The stock of Auxilium Pharmaceuticals (NASDAQ:AUXL), a specialty biopharmaceutical company, corrected almost 45% in the last 10 months from its 52-week high at $25.54 in the absence of any meaningful catalysts. Since May the stock gradually started to build a positive momentum again after creating a 52-week low at $13.87. Currently Auxilium is consolidating just below $18, and I feel slowly but steadily the stock is heading towards $25 again. In this investment thesis I will explain why the stock is worth buying at the current level with ~75% upside in the next one year.
Auxilium, together with its subsidiaries, develops and markets specialty pharmaceutical products worldwide. Auxilium's lead two products are Testim and Xiaflex. Testim
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|